IMPD-Q-only application

Phase 2

Not yet recruiting

• Conditions: IMPD-Q-only application

• Registration Number: 2024-516806-49-00
• Lead Sponsor: AstraZeneca AB

Brief Summary

IMPD-Q-only application

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-11-11
• Last Update Posted: 2024-11-11

Recruitment & Eligibility

• Status: Authorised, recruitment pending
• Sex: Not specified
• Target Recruitment: 39

Inclusion Criteria

IMPD-Q-only application

Exclusion Criteria

IMPD-Q-only application

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IMPD-Q-only application		IMPD-Q-only application

Trial Locations

Locations (5)

Vivantes Netzwerk fuer Gesundheit GmbH; 🇩🇪 Berlin, Germany

LungenClinic Grosshansdorf GmbH; 🇩🇪 Grosshansdorf, Germany

Klinikum der Universitaet Muenchen AöR; 🇩🇪 Munich, Germany

Medizinische Hochschule Hannover; 🇩🇪 Hanover, Germany

Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbH; 🇩🇪 Essen, Germany

Vivantes Netzwerk fuer Gesundheit GmbH

🇩🇪Berlin, Germany

Sven Glaser

Site contact

+4930130142030

klinische.forschung@vivantes.de